Zai Lab Announces Full-Year 2023 Financial Results and Recen

Total product revenue of $266.7 million for Full-Year 2023, representing 25% y-o-y growth; 31% y-o-y growth at constant exchange rate




VYVGART® was launched in September 2023 in China and we...

Related Keywords

Macau , Hong Kong , United States , Taiwan , China , Efgartigimod Fcrn , Josh Smiley , Zai Lab , National Medical Products Administration , Clinical Development , Zai Lab Forward , Exchange Commission , Drug Administration , Zai Lab Limited , Chief Executive Officer , Chief Operating Officer , American Deposit Share , Treating Fields , Greater China , Premarket Approval , Tumor Treating Fields , Marketing Authorization Application , Bristol Myers Squibb , Prescription Drug User Fee Act , New Drug Application , Infectious Disease , Biologics License Application , Major Milestones , Tumor Proportion Score , Tissue Factor , Autoimmune Disorders , Infectious Diseases , Private Securities Litigation Reform Act , Ended December , Share Subdivision , Markets ,